Portal de investigação
Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Albshesh, A
- Taylor, J
- Savarino, EV
- Truyens, M
- Armuzzi, A
- Ribaldone, DG
- Shitrit, ABG
- Fibelman, M
- Molander, P
- Liefferinckx, C
- Nancey, S
- Korani, M
- Rutka, M
- Barreiro-de Acosta, M
- Domislovic, V
- Suris, G
- Eriksson, C
- Alves, C
- Mpitouli, A
- di Jiang, C
- Tepes, K
- Coletta, M
- Foteinogiannopoulou, K
- Gisbert, JP
- Amir-Barak, H
- Attauabi, M
- Seidelin, J
- Afif, W
- Marinelli, C
- Lobaton, T
- Pugliese, D
- Maharshak, N
- Cremer, A
- Limdi, JK
- Molnár, T
- Otero-Alvarin, B
- Krznaric, Z
- Karmiris, K
- Raine, T
- Drobne, D
- Koutroubakis, I
- Chaparro, M
- Yanai, H
- Burisch, J
- Kopylov, U
Unidades de investigação
Abstract
Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn's disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16-22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.
Dados da publicação
- ISSN/ISSNe:
- 2077-0383, 2077-0383
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.3390/jcm10132914
- Link para outro recurso:
- www.scopus.com
Journal of Clinical Medicine MDPI AG
Citações Recebidas na Web of Science: 8
Citações Recebidas na Scopus: 12
Documentos
- Não há documentos
Filiações
Keywords
- Crohn's disease; anti-TNF failure; treatment response; treatment failure; ustekinumab; vedolizumab
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
Albshesh A,Taylor J,Savarino EV,Truyens M,Armuzzi A,Ribaldone DG,Shitrit A,Fibelman M,Molander P,Liefferinckx C,Nancey S,Korani M,Rutka M,Barreiro M,Domislovic V,Suris G,Eriksson C,Alves C,Mpitouli A,di C,Tepes K,Coletta M,Foteinogiannopoulou K,Gisbert JP,Amir H,Attauabi M,Seidelin J,Afif W,Marinelli C,Lobaton T,Pugliese D,Maharshak N,Cremer A,Limdi JK,Molnár T,Otero B,Krznaric Z,Magro F,Karmiris K,Raine T,Drobne D,Koutroubakis I,Chaparro M,Yanai H,Burisch J,Kopylov U. Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. J. Clin. Med. 2021. 10. (13):2914. IF:4,964. (2).
